Artiva Biotherapeutics (NASDAQ:ARTV) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q1 2025 earnings at ($0.68) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

ARTV has been the topic of several other reports. Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Wedbush reissued an "outperform" rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Finally, Cantor Fitzgerald dropped their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics presently has an average rating of "Buy" and a consensus target price of $20.40.

Artiva Biotherapeutics Stock Down 10.7 %

Shares of ARTV traded down $0.38 during mid-day trading on Wednesday, hitting $3.16. The company's stock had a trading volume of 80,335 shares, compared to its average volume of 114,168. Artiva Biotherapeutics has a 1-year low of $3.15 and a 1-year high of $17.31. The firm has a 50-day simple moving average of $4.71 and a 200 day simple moving average of $9.21.

Remove Ads

Institutional Trading of Artiva Biotherapeutics

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in Artiva Biotherapeutics during the fourth quarter worth approximately $52,000. Wells Fargo & Company MN grew its stake in Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after acquiring an additional 3,361 shares during the period. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.